Prophylaxis and management of thromboembolism in pnh patients: an italian survey
Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria:
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Fueling Your Journey: Nutrition Support for Aplastic Anemia, MDS, and PNH
Topic(s)
Aplastic Anemia
Living Well with Bone Marrow Failure
Managing Your Treatment
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
In this webinar, Sondos Khattab, Registered Dietitian, will discuss practical tips for managing treatment-related challenges, food safety, and making informed nutrition choices to support overall health. Questions can be submitted in advance at help@aamds.org.
What is my diagnosis? From the 2026 AAMDSIF Patient and Family Conference
Topic(s)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Bart Scott, MD
Dr. Bart Scott provides an overview of aplastic anemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and paroxysmal nocturnal hemoglobinuria (PNH). He explains the diagnostic tests and criteria used to make an accurate diagnosis.
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy
Patients with paroxysmal nocturnal hemoglobinuria
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Original Publication Date
Article Source
External Web Content
Summary Donor cell-derived haematological neoplasms (DDHN) are rare disorders and currently do not have standardised diagnostic criteria and therapeutic management. International experts in allogeneic transplantation and haematological malignancies from Europe, the Americas, and…
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy
Patients with paroxysmal nocturnal hemoglobinuria
Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry
Ravulizumab, a second-generation complement component 5 inhibitor (C5i) derived from eculizumab eculizumab:
2026 New Brunswick Patient and Family Conference
CONFERENCE LOCATION:
Heldrich Hotel
10 Livingston Avenue
New Brunswick, NJ 08901
Parking:
Complimentary hotel valet parking
Cord Blood Transplant
Topic(s)
Bone Marrow Transplant
Presenter(s)
Filippo Milano, MD, PhD
During this webinar, Dr. Filippo Milano will discuss cord blood transplant and its role in treating blood cancers and hematological disorders. He will discuss the unique benefits of cord blood as a stem cell source, recent advances in transplantation techniques, and strategies to…